Literature DB >> 8565998

Stenotrophomonas maltophilia in cystic fibrosis patients.

S Ballestero, I Vírseda, H Escobar, L Suárez, F Baquero.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8565998     DOI： 10.1007/bf01690887

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  5 in total

1.  Nosocomial infection caused by Xanthomonas maltophilia: a case-control study of predisposing factors.

Authors:  L S Elting; N Khardori; G P Bodey; V Fainstein
Journal:  Infect Control Hosp Epidemiol       Date:  1990-03       Impact factor: 3.254

2.  Septicemia due to Xanthomonas species and non-aeruginosa Pseudomonas species: increasing incidence of catheter-related infections.

Authors:  L S Elting; G P Bodey
Journal:  Medicine (Baltimore)       Date:  1990-09       Impact factor: 1.889

3.  Occurrence of nonfermentative gram-negative rods other than Pseudomonas aeruginosa in the respiratory tract of children with cystic fibrosis.

Authors:  R S Baltimore; K Radnay-Baltimore; A von Graevenitz; T F Dolan
Journal:  Helv Paediatr Acta       Date:  1982

4.  Controlled study of Pseudomonas cepacia and Pseudomonas maltophilia in cystic fibrosis.

Authors:  G Gladman; P J Connor; R F Williams; T J David
Journal:  Arch Dis Child       Date:  1992-02       Impact factor: 3.791

5.  Biochemical properties of inducible beta-lactamases produced from Xanthomonas maltophilia.

Authors:  R Paton; R S Miles; S G Amyes
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191
  5 in total
  22 in total

1.  Multiple antibiotic resistance in Stenotrophomonas maltophilia: involvement of a multidrug efflux system.

Authors:  L Zhang; X Z Li; K Poole
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Role of anti-pseudomonal antibiotics in the emergence of Stenotrophomonas maltophilia in cystic fibrosis patients.

Authors:  M Denton; N J Todd; J M Littlewood
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-05       Impact factor: 3.267

Review 3.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 4.  Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis.

Authors:  Reshma Amin; Valerie Waters
Journal:  Cochrane Database Syst Rev       Date:  2016-07-14

5.  Identification and detection of Stenotrophomonas maltophilia by rRNA-directed PCR.

Authors:  P W Whitby; K B Carter; J L Burns; J A Royall; J J LiPuma; T L Stull
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

6.  Characterization of the chromosomal aac(6')-Iz gene of Stenotrophomonas maltophilia.

Authors:  T Lambert; M C Ploy; F Denis; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

Review 7.  The changing microbial epidemiology in cystic fibrosis.

Authors:  John J Lipuma
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

8.  Isolation and characterization of novel giant Stenotrophomonas maltophilia phage phiSMA5.

Authors:  Hsiao-Chuan Chang; Chiy-Rong Chen; Juey-Wen Lin; Gwan-Han Shen; Kai-Ming Chang; Yi-Hsiung Tseng; Shu-Fen Weng
Journal:  Appl Environ Microbiol       Date:  2005-03       Impact factor: 4.792

9.  Evaluation of colistin susceptibility in multidrug-resistant clinical isolates from cystic fibrosis, France.

Authors:  S Biswas; J-C Dubus; M Reynaud-Gaubert; N Stremler; J-M Rolain
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-05-30       Impact factor: 3.267

10.  Characterization of flagella produced by clinical strains of Stenotrophomonas maltophilia.

Authors:  Doroti de Oliveira-Garcia; Monique Dall'Agnol; Mónica Rosales; Ana C G S Azzuz; Marina B Martinez; Jorge A Girón
Journal:  Emerg Infect Dis       Date:  2002-09       Impact factor: 6.883
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.